La cadena de opciones muestra datos clave de las opciones de acciones de Matinas BioPharma Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Matinas BioPharma Hldgs..

Matinas BioPharma Hldgs (AMEX:MTNB) Bolsa, Cadena de Opciones

Matinas BioPharma Hldgs

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Holdings Inc

Piper Sandler analyst David Westenberg maintains Elanco Animal Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELAN#NYSE">ELAN</a>) with a Neutral and lowers the price target from $16 to $12.

News

Price Target

Analyst Ratings

ELAN

Piper Sandler Maintains Neutral on Elanco Animal Health, Lowers Price Target to $12

Greenidge Generation Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) reported quarterly sales of $14.80 million which beat the analyst consensus estimate of $13.60 million by 8.82 percent. This is a 24.49 percent decrease over sales of $19.60 million the same period last year.

Earnings

GREE

Greenidge Generation Hldg Q4 Sales $14.80M Beat $13.60M Estimate

Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) has outperformed the market over the past 10 years by 1.08% on an annualized basis producing an average annual return of 11.98%. Currently, Workday has a market capitalization of $67.86 billion. 
Buying $1000 In WDAY: If an investor had bought $1000 of WDAY stock 10 years ago, it would be worth $3,139.75 today based on a price of $255.10 for WDAY at the time of writing.
<h3>Workday's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741271414_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

WDAY

$1000 Invested In Workday 10 Years Ago Would Be Worth This Much Today

Stephens &amp; Co. analyst John Campbell reiterates LendingTree (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TREE#NASDAQ">TREE</a>) with a Overweight and maintains $69 price target.

Reiteration

TREE

Stephens & Co. Reiterates Overweight on LendingTree, Maintains $69 Price Target

Barclays analyst Jeff Kessler maintains Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Equal-Weight and lowers the price target from $32 to $26.

Barclays Maintains Equal-Weight on Dine Brands Global, Lowers Price Target to $26

ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) saw its shares rise in the premarket session on Thursday after announcing a major partnership with Volkswagen AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/VWAGY#OTC">VWAGY</a>).
The collaboration will see ECARX provide advanced digital cockpit solutions for vehicles sold under the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44160588/ecarx-to-provide-volkswagen-brazil-and-skoda-with-digital-cockpit-solutions" rel="noreferrer noopener">Volkswagen and Skoda brands globally.</a>
This partnership will involve ECARX supplying a complete digital cockpit solution, which includes both the hardware and software for the ECARX Antora 1000 computing platform and ECARX Cloudpeak software architecture.
The initial phase of this collaboration will focus on launching vehicles in Brazil and India, with plans to expand into additional markets.
The ECARX Antora 1000 is a fourth-generation computing platform powered by a 7nm SE1000 System-on-Chip (SoC) from SiEngine.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44162646/whats-going-on-with-united-microelectronics-stock-today" rel="noreferrer noopener">What&#8217;s Going On With United Microelectronics Stock Today?</a>
The ECARX Cloudpeak software stack, based on Android Automotive OS and Linux, integrates essential services such as Google Maps, Google Assistant, and Google Play, along with mobile integrations like Android Auto and Apple CarPlay.
Ziyu Shen, Chairman and CEO of ECARX, expressed excitement about the opportunity to partner with one of the most respected automakers in the world.
&#8220;This awarding by the Volkswagen Group is a great opportunity for ECARX to partner with one of the most well-known and respected automakers in the world, and also a significant step forward for ECARX as a global company, partnering with international OEMs to deliver the best in intelligent automotive technology,&#8221; Shen added.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, ECX stock has gained over 19% in the past year.
Price Action: ECX shares are trading higher by 20.8% to $2.91 premarket at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44138085/donald-trumps-bitcoin-ethereum-xrp-reserve-is-imperfect-but-bullish-says-bitwises-matt-hougan" target="_blank" rel="noreferrer noopener">Donald Trump's Bitcoin, Ethereum, XRP Reserve Is ‘Imperfect' But Bullish, Says Bitwise's Matt Hougan</a></li>
</ul>
Image via Shutterstock.

Equities

Contracts

Markets

Movers

General

VWAGY

Why Is ECARX Holdings Stock Gaining Today?

Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) will release its second-quarter financial results, after the <a href="https://www.benzinga.com/quote/COST/earnings">closing bell, on Thursday, March 6.</a>
Analysts expect the company to report quarterly earnings at $4.11 per share, up from $3.92 per share in the year-ago period. Costco projects quarterly revenue of $63.08 billion, compared to $58.44 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Costco has missed analyst revenue estimates in two straight quarters and six of the last 10 quarters overall.
With the recent buzz around Costco, some investors may be eyeing potential gains from the company's dividends too. As of now, Costco offers an annual dividend yield of 0.44%, which is a quarterly dividend amount of $1.16 per share ($4.64 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $1,354,741 or around 1,293 shares. For a more modest $100 per month or $1,200 per year, you would need $271,367 or around 259 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($4.64 in this case). So, $6,000 / $4.64 = 1,293 ($500 per month), and $1,200 / $4.64 = 259 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
COST Price Action: Shares of Costco gained 1.1% to close at $1,047.75 on Wednesday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo: Shutterstock

Long Ideas

COST

How To Earn $500 A Month From Costco Stock Ahead Of Q2 Earnings

Barclays analyst Christine Cho maintains Array Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARRY#NASDAQ">ARRY</a>) with a Overweight and lowers the price target from $9 to $8.

ARRY

Barclays Maintains Overweight on Array Technologies, Lowers Price Target to $8

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst Michael Yee upgraded ALX Oncology Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) from Hold to Buy and raised the price target from $2 to $3. ALX Oncology shares closed at $1.04 on Wednesday. <a href="https://www.benzinga.com/quote/alxo/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst Kenneth Zener upgraded D.R. Horton, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) from Neutral to Buy and announced a $164 price target. D.R. Horton shares closed at $129.37 on Wednesday. <a href="https://www.benzinga.com/quote/dhi/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Rosenblatt analyst Catharine Trebnick upgraded the rating for Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) from Neutral to Buy and raised the price target from $190 to $235. Zscaler shares closed at $196.45 on Wednesday. <a href="https://www.benzinga.com/quote/zs/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Deutsche Bank analyst Abhi Agarwal upgraded Freeport-McMoRan Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Hold to Buy and maintained the price target of $47. Freeport-McMoRan shares closed at $38.16 on Wednesday. <a href="https://www.benzinga.com/quote/fcx/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Todd Thomas upgraded CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) from Sector Weight to Overweight and announced a $47 price target. CubeSmart shares closed at $42.46 on Wednesday. <a href="https://www.benzinga.com/quote/cube/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ZS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="549" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19-1024x549.png" alt="" class="wp-image-812281" style="width:550px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19-1024x549.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19-300x161.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19-768x412.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/06092334/image-19.png 1165w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a>

Upgrades

ALXO

CUBE

This Zscaler Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday

Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) announced today that it has acquired Alternative Power Generation, Inc. (APG), an electrical engineering and construction management firm, in a stock purchase that closed on March 3. APG adds significant expertise in data center substation design and construction management, microgrids, EV charging stations, and renewable energy projects for the commercial sector. This expertise strengthens Willdan's position in electrical engineering and enhances its capabilities in the energy transition. In 2024, APG generated approximately $37 million in revenue. Transaction terms were not disclosed.

WLDN

Willdan Announces The Acquisition of APG; In 2024, APG Generated ~$37M In Revenue; Transaction Terms Were Not Disclosed

Stephens &amp; Co. analyst Pooran Sharma reiterates Cal-Maine Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) with a Equal-Weight and maintains $97 price target.

CALM

Stephens & Co. Reiterates Equal-Weight on Cal-Maine Foods, Maintains $97 Price Target

Piper Sandler analyst Christopher Raymond maintains ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) with a Overweight and raises the price target from $8 to $9.

Piper Sandler Maintains Overweight on ALX Oncology Holdings, Raises Price Target to $9

Stephens &amp; Co. analyst Jeff Garro maintains Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) with a Equal-Weight and lowers the price target from $7 to $5.

HCAT

Stephens & Co. Maintains Equal-Weight on Health Catalyst, Lowers Price Target to $5

<ul>
<li>TSLA</li>
<li>NVDA</li>
<li>MSTR</li>
<li>LUNR</li>
<li>WAR</li>
<li>BABA</li>
<li>GLD</li>
<li>CORN</li>
<li>AMD</li>
<li>WEN</li>
</ul>
Data From <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

BABA

CORN

LUNR

MSTR

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of March 6, 2025 (Via Swaggy Stocks)

Stephens &amp; Co. analyst John Campbell maintains Descartes Systems Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGX#NASDAQ">DSGX</a>) with a Overweight and lowers the price target from $145 to $137.

DSGX

Stephens & Co. Maintains Overweight on Descartes Systems Gr, Lowers Price Target to $137

Victorias Secret &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>) shares are trading lower premarket on Thursday after the company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44152215/victorias-secret-co-reports-fourth-quarter-2024-results" rel="noreferrer noopener">reported&nbsp;fourth-quarter&nbsp;results yesterday</a>.
Revenue rose&nbsp;1%&nbsp;year over year to&nbsp;$2.11&nbsp;billion, beating the consensus of&nbsp;$2.09 billion.
Total comparable sales for the quarter&nbsp;increased&nbsp;5%. Holiday results saw sales up in both Victoria&#8217;s Secret and PINK brands as well as Beauty business.
Adjusted operating income&nbsp;rose to&nbsp;$299&nbsp;million&nbsp;from&nbsp;$283&nbsp;million&nbsp;a year ago quarter.
In the fourth quarter of 2024, the company revised its accounting estimate which led to a cumulative change that increased net sales, gross margin, and operating income by approximately $26 million.
Adjusted EPS&nbsp;of&nbsp;$2.60 beat&nbsp;the consensus of&nbsp;$2.30, vs.&nbsp;guidance&nbsp;for&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/12/42365539/victorias-secret-lifts-fy24-guidance-after-strong-q3-sees-holiday-momentum" rel="noreferrer noopener">adjusted EPS of&nbsp;$2.00 –&nbsp;$2.30</a>.
CEO&nbsp;Hillary Super said, &#8220;Sales increased across most major merchandise categories, in our stores and digital channels, and in both our North America and International businesses. We won in the big moments of the quarter and gained more than our fair share of the traffic in the mall and online.&#8221;
Related Read: <a target="_blank" href="https://www.benzinga.com/25/01/43317266/victorias-secret-shares-drop-following-cfo-transition-announcement-whats-going-on" rel="noreferrer noopener">Victoria&#8217;s Secret Shares Drop Following CFO Transition Announcement</a>
&#8220;As we look forward to 2025 and the future, we recognize there are near-term headwinds and ongoing uncertainty in the macro environment which we will manage aggressively while also working to build upon our solid foundation, realize the full potential of our brands and drive long-term, sustainable growth.&#8221;
Outlook: For the&nbsp;first quarter, Victoria&#8217;s Secret expects&nbsp;net sales of&nbsp;$1.30 billion &#8211; $1.33 billion vs. consensus of $1.39 billion&nbsp;and adjusted operating <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">income of $10 million &#8211; $30 million</a>.
Victoria&#8217;s Secret expects FY25 net sales of $6.2 billion &#8211; $6.3 billion&nbsp;vs. consensus of $6.34 billion and adjusted operating income of $300 million to $350 million.
Price Action: VSCO shares are down 5.45% at $21.00 premarket at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44146094/wall-street-awaits-trumps-tariff-decision-digests-mixed-economic-data-whats-driving-markets-wednesday" target="_blank" rel="noreferrer noopener">Wall Street Awaits Trump&#8217;s Tariff Decision, Digests Mixed Economic Data: What&#8217;s Driving Markets Wednesday?</a></li>
</ul>
Photo via Shutterstock.

Large Cap

Guidance

VSCO

Victoria's Secret Delivers Solid Q4 Results, But CEO Warns Of 'Near-Term Headwinds'

Wedbush analyst Daniel Ives maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Outperform and lowers the price target from $360 to $300.

Wedbush Maintains Outperform on MongoDB, Lowers Price Target to $300

Wedbush analyst Daniel Ives maintains Zscaler (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) with a Outperform and raises the price target from $230 to $240.

Wedbush Maintains Outperform on Zscaler, Raises Price Target to $240

WIIM

Superior Industries International shares are trading higher after the company reported a Q4 EPS beat.

Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) has outperformed the market over the past 15 years by 4.75% on an annualized basis producing an average annual return of 16.15%. Currently, Marriott International has a market capitalization of $73.89 billion. 
Buying $100 In MAR: If an investor had bought $100 of MAR stock 15 years ago, it would be worth $956.94 today based on a price of $268.00 for MAR at the time of writing.
<h3>Marriott International's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741270509_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Marriott International 15 Years Ago Would Be Worth This Much Today

Press Releases

New In Vitro Data Showing Matinas BioPharma's LNC Platform Delivering Small Oligonucleotides Presented at TIDES USA 2024

Health Care

Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Expert Dr. David S. Perlin

Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in its Oral MAT2203 Compassionate/Expanded Use Access Program

Comments

Matinas BioPharma Hldgs

Matinas BioPharma Hldgs (MTNB) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL